Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-09-02 Regulatory Filings
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is a Current Report. It details the completion of a business combination (merger) and includes references to financial statements of the acquired business, including audited and unaudited financial statements, pro forma financial information, and management's discussion and analysis. The document includes detailed financial data and exhibits with financial statements and MD&A. The presence of comprehensive financial statements and MD&A within the filing indicates it is a substantive financial report rather than a mere announcement or certification. The content aligns with a Current Report on Form 8-K/A that includes financial statements related to a merger, which is typically classified under Regulatory Filings (RNS) because 8-K filings are current reports and not annual or quarterly reports themselves. However, since the document contains detailed financial statements and MD&A incorporated by reference, and the primary purpose is to report the merger and related financial information, the best fitting category is Regulatory Filings (RNS) as 8-K/A filings are not annual or interim reports but current event reports with financial disclosures. Therefore, the classification is RNS with high confidence.
2016-09-02 English
FORM 4/A -
Director's Dealing
2016-08-23 English
FORM 4/A -
Director's Dealing
2016-08-23 English
FORM 4/A -
Director's Dealing
2016-08-23 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2016. The key content is the appointment of a new director, Richard S. Levy, M.D., to the Board of Directors of Madrigal Pharmaceuticals, Inc. It details his background, committee appointments, and compensation arrangements. The document does not contain financial statements or earnings data, nor does it announce voting results or capital changes. The primary focus is on a change in the company's board of directors. Therefore, this filing fits the category of Board/Management Information (MANG). The document length is 6662 characters, which is sufficient to contain detailed information about the appointment rather than just a brief announcement. Hence, the classification is MANG with high confidence.
2016-08-11 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-08-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.